We are live on ! Find out more
CCM

Catalio Capital Management Portfolio holdings

AUM $479M
1-Year Est. Return 140.7%
This Fund
S&P 500
This Quarter Est. Return
+25.45%
1 Year Est. Return
+140.7%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$566M
AUM Growth
+$24.9M
Cap. Flow
-$80.8M
Cap. Flow %
-14.28%
Top 10 Hldgs %
51.19%
Holding
52
New
14
Increased
5
Reduced
20
Closed
7

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$35.2M
2
BMY icon
Bristol-Myers Squibb
BMY
+$31.2M
3
JNJ icon
Johnson & Johnson
JNJ
+$23.9M
4
EW icon
Edwards Lifesciences
EW
+$15.4M
5
MLYS icon
Mineralys Therapeutics
MLYS
+$13.3M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$35.9M
2
BBIO icon
BridgeBio Pharma
BBIO
+$32.3M
3
LLY icon
Eli Lilly
LLY
+$30.1M
4
ISRG icon
Intuitive Surgical
ISRG
+$23.5M
5
NTRA icon
Natera
NTRA
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRON icon
26
Disc Medicine
IRON
$2.97B
$8.77M 1.55%
110,427
-106,100
-49% -$8.97M
OCUL icon
27
Ocular Therapeutix
OCUL
$2.02B
$8.67M 1.53%
+714,501
New +$8.68M
SEPN
28
Septerna Inc
SEPN
$1.75B
$8.21M 1.45%
294,360
– –
TARA icon
29
Protara Therapeutics
TARA
$232M
$7.71M 1.36%
1,446,254
-54,539
-4% -$303K
QURE icon
30
uniQure
QURE
$3.22B
$6.9M 1.22%
288,345
+5,405
+2% +$209K
OLMA icon
31
Olema Pharmaceuticals
OLMA
$1.05B
$6.68M 1.18%
+267,058
New +$4.75M
TERN
32
DELISTED
Terns Pharmaceuticals
TERN
$5.53M 0.98%
+136,958
New +$3.17M
RARE icon
33
Ultragenyx Pharmaceutical
RARE
$2.55B
$3.74M 0.66%
162,550
-128,712
-44% -$4.23M
HTFL
34
Heartflow Inc
HTFL
$2.49B
$3.32M 0.59%
+113,857
New +$3.67M
GRAL
35
GRAIL Inc
GRAL
$3.1B
$2.59M 0.46%
30,313
-107,615
-78% -$9.3M
FULC icon
36
Fulcrum Therapeutics
FULC
$297M
$2.28M 0.4%
+201,301
New +$2.05M
BLLN
37
BillionToOne Inc
BLLN
$4.41B
$2.09M 0.37%
+25,505
New +$2.59M
ELDN icon
38
Eledon Pharmaceuticals
ELDN
$285M
$1.9M 0.34%
1,259,820
+198,688
+19% +$472K
HYPR icon
39
Hyperfine
HYPR
$101M
$1.29M 0.23%
1,320,041
+635,500
+93% +$766K
PVLA
40
Palvella Therapeutics
PVLA
$2.27B
$1.09M 0.19%
10,452
-1,558
-13% -$133K
KPTI icon
41
Karyopharm Therapeutics
KPTI
$48M
$1.05M 0.19%
142,984
– –
MGX icon
42
Metagenomi Therapeutics
MGX
$46.3M
$857K 0.15%
528,993
– –
ATAI icon
43
AtaiBeckley Inc
ATAI
$2.68B
$805K 0.14%
196,858
– –
OM icon
44
Outset Medical
OM
$90.8M
$439K 0.08%
118,279
– –
FTH
45
Faeth Therapeutics
FTH
$629M
$157K 0.03%
14,718
– –
ABBV icon
46
AbbVie
ABBV
$435B
– –
-154,834
Closed -$35.9M
BBIO icon
47
BridgeBio Pharma
BBIO
$16.5B
– –
-622,729
Closed -$32.3M
CDTX
48
DELISTED
Cidara Therapeutics
CDTX
– –
-53,333
Closed -$5.11M
EXAS
49
DELISTED
Exact Sciences
EXAS
– –
-248,987
Closed -$13.6M
MLTX icon
50
MoonLake Immunotherapeutics
MLTX
$1.55B
– –
-133,131
Closed -$955K
1
2
3

Similar funds

FFG
Frisch Financial Group Melville, New York $478M AUM 16.28% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return
DA
Dash Acquisitions Woodland Hills, California $480M AUM 4.07% 1-Year Est. Return
NQWM
Northwest Quadrant Wealth Management Bend, Oregon $481M AUM 13.55% 1-Year Est. Return
MAM
Morse Asset Management Darien, Connecticut $481M AUM 46% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM

Catalio Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Catalio Capital Management held 52 positions worth $566M, up 4.6% from $541M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Catalio Capital Management withdrew a net $80.8M in Q4 2025, closing 7 positions and reducing 20 holdings. Its most notable exit was AbbVie, an estimated $35.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Catalio Capital Management opened a new position in Gilead Sciences worth $35.5M.

  • Catalio Capital Management's largest Q4 2025 buy was Gilead Sciences: 289,312 shares worth $35.5M.
  • Catalio Capital Management added most to Boston Scientific in Q4 2025, an estimated $9.55M increase.
  • Catalio Capital Management's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $30.1M.
  • Catalio Capital Management fully exited AbbVie in Q4 2025, selling an estimated $35.9M.
  • Catalio Capital Management's ten largest holdings make up 51% of its $566M portfolio in Q4 2025.
  • Catalio Capital Management opened 14 new positions and closed 7 in Q4 2025.
  • Catalio Capital Management's portfolio value rose 4.6% quarter-over-quarter to $566M.

Based on Catalio Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.